Pleuromutilin derivative containing amino side chain and application of pleuromutilin derivative in prevention and treatment of plant diseases

Abstract

The invention provides a pleuromutilin derivative containing an amino side chain and application of the pleuromutilin derivative in prevention and treatment of plant diseases. The pleuromutilin derivative is a compound represented by a formula I, or a stereoisomer, a tautomer, an isotope derivative and a pesticide acceptable salt thereof. The pleuromutilin derivative disclosed by the invention shows excellent bacteriostatic activity on phytopathogens such as pathogenic bacteria, and particularly shows a remarkable inhibition effect on xanthomonas pathogenic bacteria and Releiella pathogenic bacteria, and particularly on Xanthomonas oryzae pv. Oryzae and Xanthomonas citri pv. Citrullis pv. Citrullis pv. Citrullis pv. Citrullis pv. Citrullis. The pleuromutilin derivative is low in preparation difficulty, and raw materials are cheap and easy to obtain. Therefore, the compound has further development value and is expected to be developed into a novel agricultural bactericide. Formula I.

Description

TECHNICAL FIELD

[0001] The present application belongs to the field of agriculture, and particularly relates to a pleuromutilin derivative containing an amine side chain and application thereof in preventing and treating plant diseases. BACKGROUND

[0002] Plant pathogens are one of the important causes of crop diseases, which invade plant tissues through wounds or natural pores, causing systemic or local diseases and causing multiple damages to agricultural production. They are transmitted by rainwater, insects or agricultural operations, and cause diseases such as wilting (such as bacterial wilt), rotting (such as soft rot), and ulceration (such as citrus Huanglongbing), which directly leads to a 20%-70% reduction in crop yield, and even absolute yield in severe cases. Using ordinary fungicides can inhibit the spread of pathogens in plants, but due to high toxicity, it causes serious environmental pollution and leads to some health problems in humans and animals. Therefore, there is an urgent need for a new type of pesticide with high efficiency, low toxicity and low residue to further control the invasion of plant diseases.

[0003] Natural products are widely present in nature, and their advantages lie in less environmental residue, which meets the trend of green agriculture. Among them, natural terpenoids are derived from plants, fungi and other organisms, and have the characteristics of high structural diversity, broad bioactivity and strong environmental compatibility. At the same time, terpenoids are usually low in toxicity or easy to degrade, which helps to reduce chemical pesticide residues and ecological risks. Pleuromutilin is a natural terpenoid, which is initially isolated from fungi, and has potential in the field of agricultural anti-pathogens due to its unique antibacterial mechanism, providing a new direction for the development of green and efficient new biological pesticides.

[0004] The present application hopes to modify the structure of the side chain of pleuromutilin, and to provide a derivative with excellent inhibitory activity against plant pathogens and application prospect as a new anti-plant pathogen drug. SUMMARY

[0005] The purpose of the present application is to obtain a pleuromutilin derivative, improve the antibacterial activity of the compound, and have excellent inhibitory activity against plant pathogens, which can be used for preventing and treating plant diseases.

[0006] In order to achieve the above purpose, the present application uses pleuromutilin and amine compounds to construct its derivatives and evaluate their antibacterial activity.

[0007] In a first aspect, the present application provides a pleuromutilin derivative containing an amine side chain, characterized in that the pleuromutilin derivative is a compound represented by formula I as shown below, or a stereoisomer, a tautomer, an isotopic derivative and a pesticide-acceptable salt thereof:

[0008] Formula I, Where X represents -NR1R2 and -NR1-(CR3R4). m -Cy1、 , ; R1 and R2 are each independently selected from H and optionally substituted alkyl groups; R3 and R4 are each independently selected from H, halogen, amino, hydroxyl, nitro, cyano, mercapto, optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, or optionally substituted alkylamine. ring Represents an optionally substituted heterocyclic alkyl group containing at least one nitrogen atom; Cy1 and Cy2 are each independently selected from optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. The substituents on the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups are selected from one or more of halogen, amino, hydroxyl, nitro, cyano, mercapto, optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, or optionally substituted alkylamine. The optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, or optionally substituted alkylamine substituents may be selected from one or more of the following groups: halogen, amino, hydroxyl, alkyloxy, nitro, cyano, mercapto; m=0, 1, 2, 3, 4, 5, 6, 7, 8; n = 0 or 1.

[0009] In some embodiments, the alkyl group is a C1-10 alkyl group, preferably a C1-8 alkyl group, a C1-6 alkyl group, or a C1-C4 alkyl group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, etc.

[0010] In some embodiments, the aryl group is a C6-10 aryl group, preferably phenyl or naphthyl (such as 1-naphthyl or 2-naphthyl).

[0011] In some embodiments, the heteroaryl group is a 5-10 member heteroaryl group. The heteroaryl group contains 1-3 heteroatoms selected from N, O, and S. The heteroaryl group is a 5-10 member heteroaryl group containing 1-3 heteroatoms selected from N, O, and S, such as a 5-6 member heteroaryl group containing 1-2 heteroatoms selected from N, O, and S, such as a pyridyl group.

[0012] In some embodiments, the cycloalkyl group is a C3-10 cycloalkyl group, preferably a C3-8 cycloalkyl group or a C3-6 cycloalkyl group, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.

[0013] In some embodiments, the heterocyclic alkyl group is a 3-10 membered heterocyclic alkyl group or a 3-8 membered heterocyclic alkyl group. The heterocyclic alkyl group contains 1-3 heteroatoms selected from N, O, and S. The heterocyclic alkyl group is a 3-10 membered heterocyclic alkyl group or a 3-8 membered heterocyclic alkyl group containing 1-3 heteroatoms selected from N, O, and S, such as containing 1-2 3-6 membered heterocyclic alkyl groups selected from N, O, and S. The heterocyclic alkyl group is a 3-10 membered heterocyclic alkyl group or a 3-8 membered heterocyclic alkyl group containing one nitrogen atom and additionally containing 0-2 heteroatoms selected from N, O, and S, such as additionally containing 0-1 3-6 membered heterocyclic alkyl groups selected from N, O, and S. The heterocyclic alkyl group may be piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl.

[0014] In some embodiments, R1 and R2 are each independently selected from H and optionally substituted C1-8 alkyl groups; R3 and R4 are each independently selected from H, halogen, amino, hydroxyl, nitro, cyano, mercapto, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkyloxy, optionally substituted C1-6 alkylthio, or optionally substituted C1-6 alkylamino. ring Represents a 3- to 10-membered heterocyclic alkyl group with optional substitution containing at least one nitrogen atom; Cy1 and Cy2 are each independently selected from optionally substituted C3-10 cycloalkyl, optionally substituted 3-10 heterocyclic alkyl, optionally substituted C6-10 aryl, or optionally substituted 5-10 heteroaryl. The substituents on the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are selected from one or more of halogen, amino, hydroxyl, nitro, cyano, mercapto, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkyloxy, optionally substituted C1-6 alkylthio, or optionally substituted C1-6 alkylamino. The optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, or optionally substituted alkylamine substituents may be selected from one or more of the following groups: halogen, amino, hydroxyl, C1-6 alkyloxy, nitro, cyano, mercapto.

[0015] In some embodiments, the halogen is F, Cl, or Br.

[0016] In some embodiments, R1 and R2 are each independently selected from H and optionally substituted C1-6 alkyl groups; preferably, R1 and R2 are each independently selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, and n-hexyl. In some embodiments, R1 is selected from H.

[0017] In some implementations, m = 1, 2, 3, or 4.

[0018] Specifically, the compound of formula I shown can be .

[0019] In some embodiments, the compound represented by Formula I is the compound represented by Formula I-1.

[0020] Formula I-1, R1 is selected from H and optionally substituted C1-6 alkyl groups; R3 and R4 are each independently selected from H, halogen, amino, hydroxyl, nitro, cyano, mercapto, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkyloxy, optionally substituted C1-6 alkylthio, or optionally substituted C1-6 alkylamino. Cy1 is selected from optional substituted C3-8 cycloalkyl groups, optional substituted 3-8 heterocyclic alkyl groups containing 1-3 heteroatoms selected from N, O, and S, optional substituted C6-10 aryl groups, and optional substituted 5-10 heteroaryl groups containing 1-3 heteroatoms selected from N, O, and S. The substituents on the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are selected from one or more of halogen, amino, hydroxyl, nitro, cyano, mercapto, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkyloxy, optionally substituted C1-6 alkylthio, or optionally substituted C1-6 alkylamino. The optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, or optionally substituted alkylamine substituents may be selected from one or more of the following groups: halogen, amino, hydroxyl, C1-6 alkyloxy, nitro, cyano, mercapto.

[0021] In some implementations, m = 1, 2, 3, 4.

[0022] In some embodiments, R1 is selected from H and C1-6 alkyl; preferably, R1 is selected from H.

[0023] In some embodiments, R3 and R4 are each independently selected from H and C1-6 alkyl groups; preferably, R3 and R4 are each independently selected from H.

[0024] In some embodiments, Cy1 is selected from optionally substituted C3-6 cycloalkyl groups, optionally substituted 3-6-membered heterocycloalkyl groups containing 1-2 heteroatoms selected from N, O, and S, optionally substituted phenyl groups, and optionally substituted 5-6-membered heteroaryl groups containing 1-2 heteroatoms selected from N, O, and S. Preferably, Cy1 is selected from optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclohexyl, optionally substituted piperidinyl (e.g., 1-piperidinyl), optionally substituted morpholinyl (e.g., 1-morpholinyl, 4-morpholinyl), optionally substituted thiomorpholinyl (e.g., 1-thiomorpholinyl, 4-thiomorpholinyl), optionally substituted piperazine (e.g., 1-piperazine), optionally substituted phenyl, optionally substituted pyridinyl (e.g., 2-pyridinyl, 3-pyridinyl), etc.

[0025] In some embodiments, the substituents on Cy1 are selected from one or more of halogens, amino groups, hydroxyl groups, nitro groups, cyano groups, mercapto groups, C1-6 alkyl groups, C1-6 haloalkyl groups, C1-6 haloalkyloxy groups, hydroxy-substituted C1-6 alkyl groups, C1-6 alkyloxy groups, and C1-6 alkyloxy groups. Preferably, the substituents on Cy1 are selected from one or more of F, Cl, Br, amino groups, hydroxyl groups, nitro groups, cyano groups, mercapto groups, methyl groups, ethyl groups, n-propyl groups, isopropyl groups, n-butyl groups, hydroxymethyl groups, hydroxyethyl groups, methoxy groups, ethoxy groups, trifluoromethyl groups, and trifluoromethoxy groups. When there are multiple substituents on Cy1, they can be the same or different, and there can be one or two substituents on Cy1.

[0026] In some implementations, m = 1 or 2.

[0027] Specifically, the compound represented by Formula I-1 is one of the following compounds JD-10 to JD-11, JD-13 to JD-17, and JD-19 to JD-20:

[0028] .

[0029] In some embodiments, the compound represented by Formula I is the compound represented by Formula I-2.

[0030] Formula I-2, Among them, ring It represents a 3-8 membered heterocyclic alkyl group with optional substitution containing at least one nitrogen atom and additionally containing 0-2 heteroatoms selected from N, O, and S; The substituents on the heterocyclic alkyl group are selected from one or more of halogen, amino, hydroxy, nitro, cyano, mercapto, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkyloxy, optionally substituted C1-6 alkylthio, or optionally substituted C1-6 alkylamino. The optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, or optionally substituted alkylamine substituents may be selected from one or more of the following groups: halogen, amino, hydroxyl, C1-6 alkyloxy, nitro, cyano, mercapto.

[0031] In some implementations, ring Represents an optionally substituted 3-6 membered heterocyclic alkyl group containing at least one nitrogen atom, and additionally containing 0-1 heteroatoms selected from N, O, and S; preferably, the ring... Represents optionally substituted piperidinyl (e.g., 1-piperidinyl), optionally substituted morpholinyl (e.g., 1-morpholinyl, 4-morpholinyl), optionally substituted thiomorpholinyl (e.g., 1-thiomorpholinyl, 4-thiomorpholinyl), and optionally substituted piperazine (e.g., 1-piperazine).

[0032] In some embodiments, the ring The substituents are selected from one or more of halogens, amino groups, hydroxyl groups, nitro groups, cyano groups, mercapto groups, C1-6 alkyl groups, C1-6 haloalkyl groups, C1-6 haloalkyloxy groups, hydroxy-substituted C1-6 alkyl groups, C1-6 alkyloxy groups, and C1-6 alkyloxy groups. Preferably, the ring... The substituents are selected from one or more of F, Cl, Br, amino, hydroxyl, nitro, cyano, mercapto, methyl, ethyl, n-propyl, isopropyl, n-butyl, hydroxymethyl, hydroxyethyl, methoxy, ethoxy, trifluoromethyl, and trifluoromethoxy. (Ring) When there are multiple substituents on the ring, they can be the same or different. The substituents on it can be one or two.

[0033] Specifically, the compound represented by Formula I-2 is one of the following compounds: JD-1, JD-2, JD-4, JD6, and JD8: .

[0034] In some embodiments, the compound represented by Formula I is the compound represented by Formulas I-3.

[0035] Formula I-3, Among them, ring It represents a 3-8 membered heterocyclic alkyl group with optional substitution containing at least one nitrogen atom and additionally containing 0-2 heteroatoms selected from N, O, and S; Cy2 is selected from optional substituted C3-8 cycloalkyl groups, optional substituted 3-8 heterocyclic alkyl groups containing 1-3 heteroatoms selected from N, O, and S, optional substituted C6-10 aryl groups, and optional substituted 5-10 heteroaryl groups containing 1-3 heteroatoms selected from N, O, and S. The substituents on the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are selected from one or more of halogen, amino, hydroxyl, nitro, cyano, mercapto, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkyloxy, optionally substituted C1-6 alkylthio, or optionally substituted C1-6 alkylamino. The optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, or optionally substituted alkylamine substituents may be selected from one or more of the following groups: halogen, amino, hydroxyl, C1-6 alkyloxy, nitro, cyano, mercapto; n = 0 or 1.

[0036] In some implementations, ring Represents an optionally substituted 3-6 membered heterocyclic alkyl group containing at least one nitrogen atom, and additionally containing 0-1 heteroatoms selected from N, O, and S; preferably, the ring... Represents optionally substituted piperidinyl (e.g., 1-piperidinyl), optionally substituted morpholinyl (e.g., 1-morpholinyl, 4-morpholinyl), optionally substituted thiomorpholinyl (e.g., 1-thiomorpholinyl, 4-thiomorpholinyl), and optionally substituted piperazineyl (e.g., 1-piperazineyl). More preferably, cyclic Represents an optionally substituted 1-piperazinyl group.

[0037] In some embodiments, the ring The substituents are selected from one or more of halogen, amino, hydroxy, nitro, cyano, mercapto, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkyloxy, hydroxy-substituted C1-6 alkyl, C1-6 alkyloxy, and C1-6 alkyloxy-C1-6 alkyl.

[0038] In some embodiments, the compound represented by Formula I-3 is the compound represented by Formula I-4.

[0039] Formula I-4.

[0040] In some embodiments, Cy2 is selected from optionally substituted C3-6 cycloalkyl groups, optionally substituted 3-6 heterocyclic alkyl groups containing 1-2 heteroatoms selected from N, O, and S, optionally substituted phenyl groups, and optionally substituted 5-6 heteroaryl groups containing 1-2 heteroatoms selected from N, O, and S. Preferably, Cy2 is selected from optionally substituted phenyl groups, optionally substituted pyridyl groups (such as 2-pyridyl, 3-pyridyl), etc.

[0041] In some embodiments, the substituents on Cy2 are selected from one or more of halogens, amino groups, hydroxyl groups, nitro groups, cyano groups, mercapto groups, C1-6 alkyl groups, C1-6 haloalkyl groups, C1-6 haloalkyloxy groups, hydroxy-substituted C1-6 alkyl groups, C1-6 alkyloxy groups, and C1-6 alkyloxy groups. Preferably, the substituents on Cy2 are selected from one or more of F, Cl, Br, amino groups, hydroxyl groups, nitro groups, cyano groups, mercapto groups, methyl groups, ethyl groups, n-propyl groups, isopropyl groups, n-butyl groups, hydroxymethyl groups, hydroxyethyl groups, methoxy groups, ethoxy groups, trifluoromethyl groups, and trifluoromethoxy groups. When there are multiple substituents on Cy2, they can be the same or different, and there can be one or two substituents on Cy2.

[0042] Specifically, the compound represented by Formula I-3 is one of the following compounds: JD-3, JD-5, JD-7, JD-9, JD-12, NJD-1 to NJD-6:

[0043] .

[0044] In a second aspect, this application provides a method for preparing the truncated pleurotin derivative, comprising the following steps: .

[0045] In some embodiments, the first step involves reacting p-toluenesulfonyl chloride in the presence of a base to prepare intermediate I, such as in an organic solvent at room temperature in the presence of an organic base (e.g., triethylamine, diisopropylethylamine).

[0046] In some embodiments, the second step involves reacting intermediate I with a corresponding amine compound (such as HNR1R2, HNR1-(CR3R4)). m -Cy1、 , Derivatives of formula I are prepared by reaction in the presence of a base and an alkali metal iodide, such as by reflux reaction in an organic solvent in the presence of an inorganic base (e.g., sodium carbonate, potassium carbonate) or sodium iodide (or potassium iodide).

[0047] For the truncated pleurotin derivative with n=1 in Formula I-4, this application also provides the following preparation method, comprising the steps shown below: .

[0048] In some embodiments, the first step involves reacting p-toluenesulfonyl chloride in the presence of a base to prepare intermediate I, such as in an organic solvent at room temperature in the presence of an organic base (e.g., triethylamine, diisopropylethylamine).

[0049] In some embodiments, the second step involves reacting intermediate I with piperazine in the presence of a base and an alkali metal iodide to prepare intermediate II, such as by reflux in an organic solvent in the presence of an inorganic base (e.g., sodium carbonate, potassium carbonate) and sodium iodide (or potassium iodide).

[0050] In some embodiments, the third step involves reacting intermediate II with the corresponding carboxylic acid compound (such as Cy2-COOH) in the presence of a base and a condensing agent, or reacting with the corresponding acyl chloride compound (such as Cy2-COCl) in the presence of a base. For example, the reaction can be carried out at room temperature in an organic solvent in the presence of an inorganic or organic base (such as triethylamine, diisopropylethylamine, etc.).

[0051] In a third aspect, this application also provides a bactericidal composition comprising at least one of the truncated pleurotin derivatives described in the first aspect of this application as an active ingredient; and optionally a pesticide-acceptable carrier and / or adjuvant.

[0052] The bactericidal composition of this application can be applied in the form of a formulation, wherein the truncated pleurotin derivative is dissolved or dispersed in a carrier as an active component or formulated into a formulation for easier dispersion when used as a bactericidal composition. The bactericidal composition can be formulated into various liquid formulations, such as soluble powders, dispersible liquids, emulsifiable concentrates, suspensions, aqueous suspensions, microemulsions, emulsions, water-in-oil emulsions, and water-dispersible granules.

[0053] The bactericidal composition of this application may contain one or more other insecticides, fungicides, herbicides, plant growth regulators, or fertilizers.

[0054] This application also discloses the application of the truncated pleurotin derivatives described in the first aspect or the bactericidal composition described in the third aspect in the prevention and control of plant diseases, for controlling plant diseases caused by plant pathogens; preferably for use in agriculture, forestry, horticulture and health fields.

[0055] In one set of embodiments, an effective amount of the truncated pleurotin derivative as described above, or the fungicide composition as described above, is applied to plants, plant propagation materials, or subsequently grown plant organs and cultivation media, cultivation materials, or cultivation spaces; or an effective amount of the truncated pleurotin derivative as described above, or the fungicide composition as described above, is used to prevent or control pathogens on wood roots.

[0056] Preferably, an effective amount of the truncated pleurotin derivative as described above or the bactericidal composition as described above is applied to the leaves, stems, roots, seeds, or soil.

[0057] In one set of embodiments, the plant pathogen is preferably a pathogenic bacterium, including but not limited to xanthomonas and Ralstonia species. Preferably, the plant pathogen is rice bacterial blight fungus, rice bacterial leaf streak fungus, citrus canker fungus, cruciferous black rot fungus, or bacterial wilt fungus (also known as Ralstonia solanacearum).

[0058] The truncated pleurotin derivatives described in the first aspect of this application or the bactericidal compositions described in the third aspect can be used in conjunction with one or more other insecticides, fungicides, herbicides, plant growth regulators, or fertilizers.

[0059] The beneficial effects of this invention are as follows: This invention synthesizes a class of truncated pleurotin derivatives containing amino side chains and systematically evaluates their inhibitory activity against a variety of plant pathogens.

[0060] Experimental results show that the truncated pleurotin derivatives described in this application exhibit excellent antibacterial activity against plant pathogens, such as pathogenic bacteria, especially against Xanthomonas and Ralstonia species, and particularly against rice bacterial blight and citrus canker.

[0061] Analysis showed that some compounds in this application exhibited excellent inhibitory effects against rice bacterial blight and citrus canker at a concentration of 100 μg / mL. The MIC values ​​of the preferred compounds could reach 6.25 μg / mL, and even 3.12 μg / mL, which were significantly better than the inhibitory activity of truncated pleurotin (MIC=25 μg / mL).

[0062] The truncated pleurotin derivatives described in this application are easy to prepare, and the raw materials are inexpensive and readily available. Therefore, these compounds have value for further development and are expected to be developed into novel agricultural fungicides. Detailed Implementation

[0063] The following provides a detailed description of specific embodiments of the present invention. It should be understood that the specific embodiments described herein are for illustrative and explanatory purposes only and are not intended to limit the scope of the invention.

[0064] The endpoints and any values ​​of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of the various ranges, the endpoint values ​​of the various ranges and individual point values, and individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.

[0065] Before describing the invention in detail, it should be understood that the terminology used herein is for describing particular embodiments only and is not intended to limit the scope of the invention, which is defined only by the appended claims. For a more complete understanding of the invention described herein, the following terms are used, and their definitions are as follows. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as understood by one of ordinary skill in the art to which this invention pertains.

[0066] Features described or illustrated as part of one or more embodiments may be used in another or more embodiments to produce further embodiments.

[0067] The “truncated pleurotin derivative” described in this application includes compounds represented by Formula I, or their stereoisomers, tautomers, isotopic compounds, and pesticide-acceptable salts; and the preferred embodiments specifically described. The stereoisomers, tautomers, isotopic compounds, or pesticide-acceptable salts of the compounds are obtained by conventional techniques in the art and exert the same or similar effects in vitro and in vivo through substantially the same mechanism of action as the compounds.

[0068] , representing that N together with the group attached thereto forms a nitrogen-containing heterocyclic alkyl group; This indicates that the cyclic group is connected to the side chain of truncated pleurotin via an N atom.

[0069] Unless otherwise stated, “optional substitution” means that the hydrogen on the substituted group is not substituted or that one or more substituted sites of the substituted group are independently substituted by a substituent, which is independently selected from one or more of deuterium, halogen, amino, hydroxyl, nitro, cyano, mercapto, oxo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkyloxy, optionally substituted alkylthio, optionally substituted alkylamine; the substituent on the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups may be one or more of deuterium, halogen, amino, hydroxyl, nitro, cyano, mercapto, oxo, optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, optionally substituted alkylamine; the substituent on the alkyl group is selected from one or more of deuterium, halogen, amino, hydroxyl, nitro, cyano, and mercapto; when the substituent is selected as “oxo”, it means that two hydrogen atoms at the same substitution position are replaced by an oxygen atom.

[0070] The terms “alkyloxy”, “alkylthio”, and “alkylamine” refer to -O-alkyl, -S-alkyl, -NH-alkyl, or dialkylamine, respectively.

[0071] The terms "alkyloxy", "alkylthio", "alkylamine", "hydroxy-substituted alkyl", "halogenated alkyl", and "alkyl" refer to a monovalent saturated aliphatic hydrocarbon group, preferably containing 1-20, 1-18, 1-16, 1-12, or 1-10 carbon atoms, more preferably 1-8 carbon atoms (C1-8 alkyl) straight-chain or branched group (the number of carbon atoms is between 1 and 8, specifically 1, 2, 3, 4, 5, 6, 7, or 8), more preferably containing 1-6 carbon atoms (i.e., C1-6 alkyl, the number of carbon atoms is between 1 and 6, specifically 1, 2, 3, 4, 5, or 6). Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, neopentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, n-heptyl, n-octyl, etc. The term "aryl" refers to a monocyclic or bicyclic aromatic carbocyclic system containing 6-10 carbon atoms. Examples of aryl groups include phenyl and naphthyl groups, such as 1-naphthyl, 2-naphthyl, 3-naphthyl, and 4-naphthyl.

[0072] The term "heteroaryl" refers to an aromatic monocyclic or polycyclic system containing a 5-14 member structure, preferably a 5-10 member structure or a 6-10 member structure, more preferably a 5-6 member structure, wherein one, two, three, four or more ring atoms are heteroatoms and the remaining atoms are carbon atoms, the heteroatoms being independently selected from O, N or S, and the number of heteroatoms is preferably one, two, three or four. A heteroaryl group can be an aromatic monocyclic group containing one to two 5-6 member structures selected from N, S, or O, or an aromatic bicyclic group containing one to three 9-10 member structures selected from N, S, or O. Examples of heteroaryl groups include, but are not limited to, furanyl, thiophene, oxazolyl, thiazolyl, isoxazolyl, oxadiazolyl, thiazolyl, pyrroloyl, pyrazolyl, imidazoleyl, triazolyl, tetrazolyl, pyridyl, pyranyl, pyrimidinyl, pyrazinyl, pyridazinyl, morpholinyl, thiodiazolyl, triazinyl, phthalazinyl, quinolinyl, isoquinolinyl, pteridinyl, purine, indoleyl, isoindoleyl, indazoleyl, benzofuranyl, benzothiophene, benzopyridyl, benzopyrimidinyl, benzopyrazinyl, benzoimidazolyl, benzophthalazinyl, pyrrolo[2,3-b]pyridyl, imidazo[1,2-a]pyridyl, pyrazolo[1,5-a]pyridyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1 [2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridinyl, pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, quinoline-2-yl, quinoline-3-yl, quinoline-4-yl, quinoline-5-yl, quinoline-6-yl, quinoline-7-yl, quinoline-8-yl, etc.

[0073] The term "cycloalkyl" refers to a saturated monocyclic, bicyclic, or tricyclic system containing 3-12 carbon atoms, wherein the monocyclic, bicyclic, or tricyclic ring does not contain an aromatic ring, including bridged cycloalkyl, spirocyclic, and fused cycloalkyl groups. Preferably, it contains 3-10 carbon atoms (C3-10 cycloalkyl), more preferably 3-8 carbon atoms (C3-8 cycloalkyl), 3-6 carbon atoms (C3-6 cycloalkyl), 4-6 carbon atoms (C4-6 cycloalkyl), or 5-6 carbon atoms (C5-6 cycloalkyl). Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0074] The term "heterocyclic alkyl" refers to a saturated monocyclic, bicyclic, or polycyclic cyclic hydrocarbon group, preferably containing 3-12 ring atoms, wherein one, two, three, or more ring atoms are selected from N, O, or S, and the remaining ring atoms are C, including bridged cyclic groups, spirocyclic groups, fused cyclic groups, etc. Preferably, it contains 3-10 ring atoms (3-10 membered heterocyclic alkyl), or 3-8 ring atoms (3-8 membered heterocyclic alkyl), or 3-6 ring atoms (3-6 membered heterocyclic alkyl), or 4-6 ring atoms (4-6 membered heterocyclic alkyl), or 5-6 ring atoms (5-6 membered heterocyclic alkyl). The number of heteroatoms is preferably 1-4, more preferably 1-3 (i.e., 1, 2, or 3). The heterocyclic alkyl group may be a 5-6 membered monocyclic heterocyclic alkyl group containing 1-2 N or O atoms. Examples of heterocyclic alkyl groups include pyrrolidinyl, imidazoalkyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, azircyclopropane, oxacyclopropane, thiohexacyclopropane, azircyclobutane, oxacyclobutane, thiohexacyclobutane, oxacyclohexane, morpholinyl, thiomorpholinyl, dioxane, dithiohexyl, oxazolyl, thiazoalkyl, pyrazolyl, imidazolinidine, tetrahydrofuran-1-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-1-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, piperidin-1-yl, piperidin-4-yl, etc.

[0075] The term "halogen" refers to F, Cl, Br, and I. The term "stereoisomer" refers to isomers resulting from different spatial arrangements of atoms in a molecule, including configurational isomers and conformational isomers. Configurational isomers include geometric isomers (or cis-trans isomers) and optical isomers (including enantiomers and diastereomers). Geometric isomers may be present in this compound. Optical isomers refer to substances with identical molecular structures and similar physicochemical properties, but different optical rotations. The compounds of this invention may contain asymmetrically substituted carbon atoms in the R or S configuration, wherein the terms "R" and "S" are as defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-10. Compounds with asymmetrically substituted carbon atoms (having equal numbers of R and S configurations) are racemic at those carbon atoms. Having an excess of atoms in one configuration (relative to another) results in a higher quantity of that configuration, preferably an excess of about 85%-90%, more preferably an excess of about 95%-99%, and even more preferably an excess greater than about 99%. Accordingly, the present invention includes racemic mixtures, relative and absolute optical isomers, and mixtures of relative and absolute optical isomers.

[0076] The term "tautomer" refers to structural isomers with different energies that can interconvert through a low energy barrier. If tautomerism is possible (e.g., in solution), chemical equilibrium can be achieved for the tautomers. For example, proton tautomers (also called proton transfer tautomers) involve interconversions via proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers involve interconversions via the rearrangement of some bonding electrons.

[0077] The term "isotope derivative" refers to compounds of the present invention that can exist in an isotopically traced or enriched form, containing one or more atoms whose atomic weights or mass numbers differ from the atomic weights or mass numbers of the most abundant atoms found in nature. Isotopes can be radioactive or non-radioactive. Isotopes of atoms such as hydrogen, carbon, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine include, but are not limited to: 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 32 P, 35 S, 18 F, 36 Cl, 80 Br and 125 I. Compounds containing these and / or other isotopes are within the scope of this invention. The isotopically labeled compounds of this invention can be prepared using general methods well known to those skilled in the art.

[0078] The term "pesticide-acceptable salt" refers to a salt obtained by reacting the truncated pleurotin derivative of this application with a chemically acceptable acid, wherein the chemically acceptable acid can be an inorganic acid or an organic acid; the pesticide-acceptable salt can also be a salt obtained by reacting the truncated pleurotin derivative of this application with a chemically acceptable base, wherein the chemically acceptable base can be an inorganic base or an organic base.

[0079] The term "pesticide-acceptable carrier" includes, but is not limited to, surfactants, including ionic and nonionic surfactants. The surfactants include emulsifiers, dispersants, or wetting agents. Specifically, the emulsifiers may be polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, polyoxyethylene fatty amines, and commercially available emulsifiers; the dispersants include sodium lignosulfonate, dispersing agents, calcium lignosulfonate, or methylnaphthalenesulfonate formaldehyde condensate, etc.; the wetting agents include sodium lauryl sulfate, sodium dodecylbenzenesulfonate, or alkylnaphthalenesulfonate, etc. The pesticide-acceptable carrier includes solid carriers and / or liquid carriers. Preferably, the solid carrier includes natural or synthetic clays and silicates, such as natural silica and diatomaceous earth; magnesium silicate, such as talc; magnesium aluminum silicate, such as kaolinite, montmorillonite, and mica; white carbon black, calcium carbonate, light calcium carbonate; calcium sulfate; limestone; sodium sulfate; and amine salts such as ammonium sulfate and hexamethylenediamine. Preferably, the liquid carrier comprises water and an organic solvent; when water is used as a solvent or diluent, the organic solvent can be used as an auxiliary agent or antifreeze additive. Preferably, the organic solvent includes aromatic hydrocarbons (e.g., benzene, xylene, or toluene), chlorinated hydrocarbons (e.g., chlorobenzene, vinyl chloride, chloroform, or dichloromethane), aliphatic hydrocarbons (e.g., petroleum fractions, cyclohexane, or light mineral oil), alcohol solvents (e.g., isopropanol, butanol, ethylene glycol, glycerol, or cyclohexanol), ether solvents, ester solvents, ketone solvents (e.g., acetone, cyclohexanone, or N-methylpyrrolidone), or dimethylformamide, etc.

[0080] The bactericide composition can be formulated by mixing the active component with a liquid carrier and / or a solid carrier, and by adding surfactants (such as emulsifiers, dispersants, stabilizers, and wetting agents), as well as other additives (such as adhesives, defoamers, and oxidants).

[0081] The present invention will be further illustrated below with reference to specific embodiments; however, these embodiments do not limit the scope of the invention. Unless otherwise stated, all reactants used in the embodiments are commercially available or can be prepared by methods known in the literature or as detailed in the description; the instruments and equipment used in the synthesis experiments and product analysis are all conventional instruments and equipment commonly used in organic synthesis. Unless otherwise specified, the experimental methods described in the following embodiments are conventional methods.

[0082] Example 1: Preparation of compounds JD-1~JD-20

[0083] Synthesis of Intermediate I: Triethylamine (7.3 mL, 53.6 mmol) was slowly added to a mixture of truncated pleurotin (10 g, 26.4 mmol) and p-toluenesulfonyl chloride (5.5 g, 5.5 g, 29.1 mmol) in 40 mL of ethyl acetate. The mixture was stirred at room temperature for 24 h. The reaction mixture was extracted with ethyl acetate, the organic phases were combined, dried over sodium sulfate, and concentrated under vacuum. The crude mixture was purified by silica gel column chromatography (PE / EtOAc 10:1 to 5:1) to give Intermediate I (yield 85%) as a white solid.

[0084] Synthesis of compounds JD-1 to JD-20: Intermediate I (1 mmol), amines with different substitutions (1.2 mmol), NaI (0.1 mmol), and K₂CO₃ (3 mmol) were dissolved in acetonitrile (10 mL) and refluxed at 90 °C for 4 hours. The mixture was extracted with dichloromethane, and the combined organic layers were dried over anhydrous Na₂SO₄ and concentrated. The solutions were purified by silica gel (petroleum ether / AcOEt, 5 / 1 v / v) column chromatography to obtain compounds JD-1 to JD-20.

[0085] Example 2: Preparation of compounds NJD-1 to NJD-6

[0086] Synthesis of intermediate I: Same as in Example 1.

[0087] Synthesis of Intermediate II: Intermediate I (1 mmol), anhydrous piperazine (1.2 mmol), NaI (0.1 mmol), and K₂CO₃ (3 mmol) were dissolved in acetonitrile (10 mL) and refluxed at 90 °C for 4 h. The mixture was extracted with dichloromethane, and the combined organic layers were dried over anhydrous Na₂SO₄ and concentrated. Intermediate II was purified by silica gel (petroleum ether / AcOEt, 5 / 1 v / v) column chromatography.

[0088] Synthesis of compounds NJD-1 to NJD-6: Intermediate II (1 mmol), pyridine acids with different substitutions (1.0 mmol), HOBT (1.2 mmol), EDCI (1.2 mmol), and TEA (3.0 mmol) were dissolved in DCM (10 mL) and reacted at room temperature for 3–4 hours. The mixture was washed three times with saturated brine, and the organic layers were combined, dried over anhydrous Na₂SO₄, and concentrated. The solutions were purified by silica gel (petroleum ether / AcOEt, 5 / 1 v / v) column chromatography to obtain compounds NJD-1 to NJD-6.

[0089] Structural characterization parameters of compounds JD-1~JD-20 and NJD-1~NJD-6 are shown in Table 1.

[0090] Table 1. Structural characterization parameters of compounds JD-1~JD-20 and NJD-1~NJD-6

[0091] Example 3: Determination of the anti-agricultural pathogenic bacteria activity of truncated pleurotin derivatives and its results 1) Test reagents: truncated pleurotin derivatives JD-1~JD-20, NJD-1~NJD-6.

[0092] 2) Test strains: PXO99A, pathogen of rice bacterial blight, and pathogen of citrus canker. Xanthomonas axonopodis pv. Citri and bacterial wilt pathogen Pseudomonas solanacearum Provided by Gansu Academy of Agricultural Sciences.

[0093] 3) Antibacterial activity test: The bacterial strains used in this experiment were cryopreserved in the laboratory at -80℃ with 30% glycerol. The cryopreserved strains were removed and streaked onto NB solid medium (beef extract: 3 g, peptone: 5 g, yeast extract: 1 g, sucrose: 10 g, agar: 15 g, distilled water: 1 L, pH 7.0; sterilized at 121℃ for 20 min), and incubated at 28℃ until single colonies appeared. Single colonies from the solid medium were transferred to NB liquid medium (beef extract: 3 g, peptone: 5 g, yeast extract: 1 g, sucrose: 10 g, distilled water: 1 L; sterilized at 121℃ for 20 min) and cultured on a shaker at 28℃ and 180 rpm until the logarithmic growth phase. The strains in the logarithmic growth phase were diluted with NB liquid medium to approximately 10... 6 CFU / mL was prepared for use. The compounds were dissolved separately in DMSO, added to liquid culture medium, and mixed thoroughly to prepare a drug-containing liquid culture medium with a concentration of 200 μg / mL. 50 μL of the drug-containing culture medium and the same volume of approximately 10... 6CFU / mL bacterial culture was added to the wells of a 96-well plate, resulting in a final drug concentration of 100 μg / mL. A control of 100 μL of bacterial culture containing an equal amount of DMSO was used. The 96-well plates were incubated at 28℃ for 24–48 h until bacterial growth was observed in the control group. The OD value (OD) of the bacterial culture in each well was measured using a microplate reader. 600 In addition, the OD values ​​of 100 μL of liquid culture medium and a 100 μg / mL drug concentration were measured to correct for the OD values ​​caused by the culture medium and the drug itself. The formulas for calculating the corrected OD value and inhibition rate are as follows: Corrected OD value = OD value of bacterial culture medium - OD value of sterile culture medium; Inhibition rate = (OD value of bacterial suspension in control medium after correction - OD value of bacterial suspension in drug-containing medium after correction) / OD value of bacterial suspension in control medium after correction × 100% The drug-containing liquid culture medium was diluted in 96-well plates using a two-fold dilution method to obtain a series of 50 μL drug-containing media. The inhibition rate corresponding to the series of concentrations was then determined according to the same experimental method described above. All experiments were performed in triplicate, and the MIC values ​​of the compound are shown in Table 2.

[0094] Table 2. In vitro MIC (μg / mL) of truncated pleurotin derivatives JD-1~JD-20 and NJD-1~NJD-6 against plant pathogenic bacteria.

[0095] As shown in Tables 2 and 3, the activity test results indicate that the truncated pleurotin derivatives prepared in this invention exhibit varying degrees of inhibitory activity against three plant pathogenic bacteria. In particular, their inhibitory activity against rice bacterial blight and citrus canker is significantly better than that against other pathogens. The MICs of JD-1, JD-4, JD-5, JD-9, JD-18, and JD-19 reach 6.25 μg / mL, and the MIC of JD-13 reaches 3.12 μg / mL, which are significantly better than the inhibitory activity of commercially available truncated pleurotin. Therefore, these compounds have the potential for further development and may be developed into novel agricultural antibacterial agents.

[0096] The preferred embodiments of the present invention have been described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the scope of the technical concept of the present invention, various simple modifications can be made to the technical solution of the present invention, and these simple modifications all fall within the protection scope of the present invention.

[0097] It should also be noted that the various specific technical features described in the above embodiments can be combined in any suitable manner without contradiction. To avoid unnecessary repetition, this invention will not describe the various possible combinations separately. As long as they do not violate the spirit of this invention, they should also be regarded as the content disclosed by this invention.

Claims

1. A truncated pleurotin derivative containing an amino side chain, characterized in that, The truncated pleurotin derivative is a compound represented by Formula I as shown below, or its stereoisomers, tautomers, isotopic derivatives, and pesticide-acceptable salts: Formula I, Where X represents -NR1R2 and -NR1-(CR3R4). m -Cy1、 , ; R1 and R2 are each independently selected from H and optionally substituted alkyl groups; R3 and R4 are each independently selected from H, halogen, amino, hydroxyl, nitro, cyano, mercapto, optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, or optionally substituted alkylamine. ring Represents an optionally substituted heterocyclic alkyl group containing at least one nitrogen atom; Cy1 and Cy2 are each independently selected from optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. The substituents on the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups are selected from one or more of halogen, amino, hydroxyl, nitro, cyano, mercapto, optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, or optionally substituted alkylamine. The optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, or optionally substituted alkylamine substituents may be selected from one or more of the following groups: halogen, amino, hydroxyl, alkyloxy, nitro, cyano, mercapto; m=0、1、2、3、4、5、6、7、8； n = 0 or 1.

2. The truncated pleurotin derivative according to claim 1, characterized in that, R1 and R2 are each independently selected from H and optionally substituted C1-8 alkyl groups; R3 and R4 are each independently selected from H, halogen, amino, hydroxyl, nitro, cyano, mercapto, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkyloxy, optionally substituted C1-6 alkylthio, or optionally substituted C1-6 alkylamino. ring Represents a 3- to 10-membered heterocyclic alkyl group with optional substitution containing at least one nitrogen atom; Cy1 and Cy2 are each independently selected from optionally substituted C3-10 cycloalkyl, optionally substituted 3-10 heterocyclic alkyl, optionally substituted C6-10 aryl, or optionally substituted 5-10 heteroaryl. The substituents on the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are selected from one or more of halogen, amino, hydroxyl, nitro, cyano, mercapto, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkyloxy, optionally substituted C1-6 alkylthio, or optionally substituted C1-6 alkylamino. The optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, or optionally substituted alkylamine substituents may be selected from one or more of the following groups: halogen, amino, hydroxyl, C1-6 alkyloxy, nitro, cyano, mercapto.

3. The truncated pleurotin derivative according to any one of claims 1-2, characterized in that, The halogens are F, Cl, and Br.

4. The truncated pleurotin derivative according to any one of claims 1-3, characterized in that, R1 and R2 are each independently selected from H and optionally substituted C1-6 alkyl groups; preferably, R1 and R2 are each independently selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, and n-hexyl; more preferably, R1 is H.

5. The truncated pleurotin derivative according to any one of claims 1-3, characterized in that, The compound represented by Formula I is the compound represented by Formula I-1; Formula I-1, R1 is selected from H and optionally substituted C1-6 alkyl groups; R3 and R4 are each independently selected from H, halogen, amino, hydroxyl, nitro, cyano, mercapto, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkyloxy, optionally substituted C1-6 alkylthio, or optionally substituted C1-6 alkylamino. Cy1 is selected from optional substituted C3-8 cycloalkyl groups, optional substituted 3-8 heterocyclic alkyl groups containing 1-3 heteroatoms selected from N, O, and S, optional substituted C6-10 aryl groups, and optional substituted 5-10 heteroaryl groups containing 1-3 heteroatoms selected from N, O, and S. The substituents on the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are selected from one or more of halogen, amino, hydroxyl, nitro, cyano, mercapto, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkyloxy, optionally substituted C1-6 alkylthio, or optionally substituted C1-6 alkylamino. The optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, or optionally substituted alkylamine substituents may be selected from one or more of the following groups: halogen, amino, hydroxyl, C1-6 alkyloxy, nitro, cyano, mercapto; m=1、2、3、4； Preferably, R1 is selected from H and C1-6 alkyl groups; R3 and R4 are each independently selected from H and C1-6 alkyl groups; Cy1 is selected from optionally substituted C3-6 cycloalkyl groups, optionally substituted 3-6 heterocyclic alkyl groups containing 1-2 heteroatoms selected from N, O, and S, optionally substituted phenyl groups, and optionally substituted 5-6 heteroaryl groups containing 1-2 heteroatoms selected from N, O, and S. More preferably, Cy1 is selected from optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclohexyl, optionally substituted piperidinyl, optionally substituted morpholinyl, optionally substituted thiomorpholinyl, optionally substituted piperazine, optionally substituted phenyl, optionally substituted pyridinyl.

6. The truncated pleurotin derivative according to claim 5, characterized in that, The substituents on Cy1 are selected from one or more of halogens, amino, hydroxyl, nitro, cyano, mercapto, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkyloxy, hydroxy-substituted C1-6 alkyl, C1-6 alkyloxy, and C1-6 alkyloxy-C1-6 alkyl; preferably, the substituents on Cy1 are selected from one or more of F, Cl, Br, amino, hydroxyl, nitro, cyano, mercapto, methyl, ethyl, n-propyl, isopropyl, n-butyl, hydroxymethyl, hydroxyethyl, methoxy, ethoxy, trifluoromethyl, and trifluoromethoxy.

7. The truncated pleurotin derivative according to any one of claims 1-3, characterized in that, The compound represented by Formula I is the same as the compound represented by Formula I-2; Formula I-2, Among them, ring It represents a 3-8 membered heterocyclic alkyl group with optional substitution containing at least one nitrogen atom and additionally containing 0-2 heteroatoms selected from N, O, and S; The substituents on the heterocyclic alkyl group are selected from one or more of halogen, amino, hydroxy, nitro, cyano, mercapto, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkyloxy, optionally substituted C1-6 alkylthio, or optionally substituted C1-6 alkylamino. The optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, or optionally substituted alkylamine substituents may be selected from one or more of the following groups: halogen, amino, hydroxyl, C1-6 alkyloxy, nitro, cyano, mercapto; Preferably, ring Represents an optionally substituted 3-6-membered heterocyclic alkyl group containing at least one nitrogen atom, and additionally containing 0-1 heteroatoms selected from N, O, and S; More preferably, in the ring Represents optional substituted piperidinyl, optional substituted morpholinyl, optional substituted thiomorpholinyl, optional substituted piperazineyl.

8. The truncated pleurotin derivative according to claim 7, characterized in that, The ring The substituents are selected from one or more of halogen, amino, hydroxy, nitro, cyano, mercapto, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkyloxy, hydroxy-substituted C1-6 alkyl, C1-6 alkyloxy, and C1-6 alkyloxy-C1-6 alkyl. Preferably, the ring The substituents are selected from one or more of F, Cl, Br, amino, hydroxyl, nitro, cyano, mercapto, methyl, ethyl, n-propyl, isopropyl, n-butyl, hydroxymethyl, hydroxyethyl, methoxy, ethoxy, trifluoromethyl, and trifluoromethoxy.

9. The truncated pleurotin derivative according to any one of claims 1-3, characterized in that, The compound represented by Formula I is the same as the compound represented by Formula I-3; Formula I-3, Among them, ring It represents a 3-8 membered heterocyclic alkyl group with optional substitution containing at least one nitrogen atom and additionally containing 0-2 heteroatoms selected from N, O, and S; Cy2 is selected from optional substituted C3-8 cycloalkyl groups, optional substituted 3-8 heterocyclic alkyl groups containing 1-3 heteroatoms selected from N, O, and S, optional substituted C6-10 aryl groups, and optional substituted 5-10 heteroaryl groups containing 1-3 heteroatoms selected from N, O, and S. The substituents on the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are selected from one or more of halogen, amino, hydroxyl, nitro, cyano, mercapto, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkyloxy, optionally substituted C1-6 alkylthio, or optionally substituted C1-6 alkylamino. The optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted alkylthio, or optionally substituted alkylamine substituents may be selected from one or more of the following groups: halogen, amino, hydroxyl, C1-6 alkyloxy, nitro, cyano, mercapto; n = 0 or 1; Preferably, ring Represents an optionally substituted 3-6-membered heterocyclic alkyl group containing at least one nitrogen atom, and additionally containing 0-1 heteroatoms selected from N, O, and S; More preferably, in the ring Represents optionally substituted piperidinyl, optionally substituted morpholinyl, optionally substituted thiomorpholinyl, optionally substituted piperazineyl; Most preferably, the compound represented by formula I-3 is the compound represented by formula I-4. Formula I-4.

10. The truncated pleurotin derivative according to claim 9, characterized in that, Cy2 is selected from optionally substituted C3-6 cycloalkyl groups, optionally substituted 3-6 heterocyclic alkyl groups containing 1-2 heteroatoms selected from N, O, and S, optionally substituted phenyl groups, and optionally substituted 5-6 heteroaryl groups containing 1-2 heteroatoms selected from N, O, and S. Preferably, Cy2 is selected from optionally substituted phenyl groups or optionally substituted pyridyl groups.

11. The truncated pleurotin derivative according to claim 10, characterized in that, The substituents on Cy2 are selected from one or more of the following: halogen, amino, hydroxyl, nitro, cyano, mercapto, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkyloxy, hydroxy-substituted C1-6 alkyl, C1-6 alkyloxy, and C1-6 alkyloxy-C1-6 alkyl. Preferably, the substituents on Cy2 are selected from one or more of F, Cl, Br, amino, hydroxyl, nitro, cyano, mercapto, methyl, ethyl, n-propyl, isopropyl, n-butyl, hydroxymethyl, hydroxyethyl, methoxy, ethoxy, trifluoromethyl, and trifluoromethoxy.

12. The truncated pleurotin derivative according to claim 1, characterized in that, The compound represented by Formula I is one of the following compounds JD-1 to JD-20 and NJD-1 to NJD-6: 。 13. A bactericidal composition, characterized in that, It contains at least one of the truncated pleurotin derivatives as described in any one of claims 1-12 as an active ingredient; and optionally a pesticide-acceptable carrier and / or adjuvant.

14. The use of the truncated pleurotin derivative according to any one of claims 1-12 or the fungicidal composition according to claim 13 in the control of plant diseases, characterized in that, It is used to control plant diseases caused by plant pathogens; preferably, the plant pathogens are pathogenic bacteria; more preferably, the plant pathogens are pathogenic bacteria of the genus Xanthomonas or Ralstonia; most preferably, the plant pathogens are rice bacterial blight fungus, rice bacterial leaf streak fungus, citrus canker fungus, cruciferous black rot fungus, and bacterial wilt fungus.

Images